Micromem develops ultrasensitive liquid-phase sensor

An anonymous director reports MICROMEM TECHNOLOGIES LAUNCHES ULTRA-SENSITIVE LIQUID-PHASE SENSOR TARGETING DISEASE BIOMARKERS WITH BREAKTHROUGH PICOMOLAR DETECTION Micromem Technologies Inc. has successfully developed its liquid-phase nanowire biochemical sensor, engineered to detect disease-associated biomarkers at ultralow concentrations. This innovation marks a critical milestone in the pursuit of more accurate, earlier medical diagnostics. The sensor has demonstrated limit-of-detection performance down to one picomolar (pM) and 20 mV (millivolts) per decade sensitivity, enabling the identification of inflammatory and pathological biomarkers previously undetectable by conventional methods. The sensor platform is fabricated using standard photolithography processes, making it both cost-effective and scalable for high-volume industrial applications. The initial target analyte is TREM-1 (triggering receptor expressed on myeloid cells), a key marker known to amplify inflammatory responses and closely associated with a range of diseases including atherosclerosis, cancer, colitis and fibrosis. Platform highlights: Ultralow detection thresholds: achieves pM-level detection, suitable for early-stage disease monitoring; Broad diagnostic utility: customizable for other critical biomarkers involved in cancer, autoimmune disease and systemic inflammation; High signal clarity: nanowire-based response delivers real-time, low-noise output with a strong correlation to analyte concentration; Compact and integratable: ready for deployment in next-generation lab-on-a-chip, point-of-care or remote diagnostic devices; Manufactured via conventional photolithography techniques, the platform supports efficient, low-cost production -- critical for widespread adoption in clinical and point-of-care diagnostics. Market relevance With global demand for biomarker diagnostics expected to exceed $100-billion (U.S.) by 2030, Micromem's platform presents a compelling opportunity for partnerships with biotech, pharmaceutical and diagnostics companies seeking next-generation sensor technologies. This liquid-phase sensor platform originated from work developed on behalf of the Department of National Defence and is evolving into a commercial diagnostic tool. Micromem is positioning its gas detection technology for integration into industrial and environmental systems through targeted partnerships and pilot initiatives. Precision medicine starts with precision detection. The company's platform offers the sensitivity, flexibility and scalability to support a wide array of clinical applications. With the platform now ready for field validation, the company is seeking co-development and deployment opportunities with strategic industry partners. Micromem is focused on expanding commercial readiness and welcomes pilot deployment opportunities. About Micromem Technologies Inc. Micromem Technologies, a publicly traded company, develops and commercializes advanced sensor solutions using proprietary nanotechnology and analyzes specific industry sectors to create intelligent game-changing applications that address unmet market needs. It creates platforms the serve the needs of industries that demand accuracy, durability and real-time intelligence in detection systems. By leveraging its expertise and experience with sophisticated sensor applications, the company successfully powers the development and implementation of innovative solutions for oil and gas, utilities, automotive, health care, government, information technology, manufacturing, and other industries. We seek Safe Harbor.